Summit Therapeutics Inc [NASDAQ: SMMT] gained 11.50% on the last trading session, reaching $21.82 price per share at the time.
If compared to the average trading volume of 2.13M shares, SMMT reached a trading volume of 3502661 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Summit Therapeutics Inc [SMMT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SMMT shares is $33.57 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SMMT stock is a recommendation set at 1.29. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Truist have made an estimate for Summit Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 08, 2025. While these analysts kept the previous recommendation, Wells Fargo raised their target price to Overweight. The new note on the price target was released on December 11, 2024, representing the official price target for Summit Therapeutics Inc stock. Previously, the target price had yet another raise to $31, while Jefferies analysts kept a Buy rating on SMMT stock.
The Average True Range (ATR) for Summit Therapeutics Inc is set at 1.56 The Price to Book ratio for the last quarter was 36.73, with the Price to Cash per share for the same quarter was set at 0.66.
Trading performance analysis for SMMT stock
Summit Therapeutics Inc [SMMT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.56. With this latest performance, SMMT shares gained by 31.05% in over the last four-week period, additionally plugging by 93.96% over the last 6 months – not to mention a rise of 367.24% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SMMT stock in for the last two-week period is set at 56.07, with the RSI for the last a single of trading hit 57.94, and the three-weeks RSI is set at 55.11 for Summit Therapeutics Inc [SMMT]. The present Moving Average for the last 50 days of trading for this stock 19.42, while it was recorded at 20.22 for the last single week of trading, and 14.95 for the last 200 days.
Summit Therapeutics Inc [SMMT]: A deeper dive into fundamental analysis
Summit Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 8.31 and a Current Ratio set at 8.31.
Summit Therapeutics Inc [SMMT]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SMMT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Summit Therapeutics Inc go to 15.48%.
An analysis of Institutional ownership at Summit Therapeutics Inc [SMMT]
The top three institutional holders of SMMT stocks are: BAKER BROS. ADVISORS LP with ownership of 23.22 million shares, which is approximately 3.309%. VANGUARD GROUP INC, holding 8.82 million shares of the stock with an approximate value of $$68.78 million in SMMT stocks shares; and VANGUARD GROUP INC, currently with $$61.61 million in SMMT stock with ownership which is approximately 1.1255%.
